cemx174 5 25 m7 cells (Cellgro)
Structured Review

Cemx174 5 25 M7 Cells, supplied by Cellgro, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cemx174 5 25 m7 cells/product/Cellgro
Average 86 stars, based on 1 article reviews
Images
1) Product Images from "The V1, V2, and V3 Regions of the Human Immunodeficiency Virus Type 1 Envelope Differentially Affect the Viral Phenotype in an Isolate-Dependent Manner"
Article Title: The V1, V2, and V3 Regions of the Human Immunodeficiency Virus Type 1 Envelope Differentially Affect the Viral Phenotype in an Isolate-Dependent Manner
Journal:
doi: 10.1128/JVI.79.14.9069-9080.2005

Figure Legend Snippet: CD4 binding and fusogenic potential of SF162 envelopes with deletions in the V3 loop. (A) The indicated deletions were introduced within the V3 loop of the SF162 envelope. The deleted sequences were replaced by the GAG tripeptide. (B) The binding of IgGCD4 to SF162 and SF162ΔV2 virions with and without deletions in the V3 loop was determined by monitoring the binding of IgGCD4 to virions. (C) The cell fusion potential of SF162 and SF162ΔV2 envelopes lacking elements of the V3 loop was assessed using U87-CD4-CCR5 as target cells. Δenv, pseudovirions lacking envelope were used as negative controls. The values represent the average and standard deviations from quadruplicate wells from a single experiment. Experiments were performed at least three times with similar results.
Techniques Used: Binding Assay

Figure Legend Snippet: Generation of the SF162ΔV1V2 virus. (A) Human PBMC were inoculated with supernatant from 293T cells that were transfected with plasmids encoding the SF162ΔV1V2 genome. Supernatant collected at day 28 post-PBMC-inoculation was used to inoculate a new batch of human PBMC. Note the difference in scale of the y-axis between the two graphs. (B) Single-round competent virions expressing the indicated envelopes were incubated with U87-CD4-CCR5 cells, as described in the Materials and Methods and cell-associated luciferase was determined 48 h later. Δenv, Virions that do not express envelope. D/N, aspartic acid at position 112 in the C1 region was replaced by asparagine. Black bars, 1 ng of p24 inoculum. White bars, 0.1 ng of p24 inoculum. Results are from one out of thee independent experiments.
Techniques Used: Transfection, Expressing, Incubation, Luciferase

Figure Legend Snippet: Processing and CD4 binding potential of SF128A-derived envelopes lacking the V2 loop. (A) 293T cells were transfected with DNA vectors expressing wither the SF128A or SF128AΔV2 (two clones, 5 and 9) gp160 envelopes. The presence of gp160 and gp120 in the cell-lysates or cell-supernatants was determined as described in the Materials and Methods section. (B) Single-round competent virions expressing the SF128A or SF128AΔV2 envelopes were purified through sucrose and then incubated with the indicated concentrations of IgGCD4. Virion-associated IgGCD4 was determined as described in the Materials and Methods section.
Techniques Used: Binding Assay, Derivative Assay, Transfection, Expressing, Clone Assay, Purification, Incubation

Figure Legend Snippet: Fusion potential of SF170 or SF128A-derived envelopes. Single-round competent virions (5 ng of p24 equivalent per well of a 96 well plate) expressing the indicated envelopes derived either from SF170 or SF128A were incubated with U87-CD4-CCR5 cells for 72 h and the cell-associated luciferase was determined. Data are the average of triplicate wells, and two independent clones each of SF170ΔV2 and SF128AΔV2 were tested in parallel with similar results.
Techniques Used: Derivative Assay, Expressing, Incubation, Luciferase, Clone Assay

Figure Legend Snippet: Neutralization susceptibility of SF162, SF162ΔV1, SF162ΔV2, and SF162ΔV1V2 viruses. The neutralization susceptibility of the indicated viruses against a panel of MAbs and sera was determined using luciferase-expressing single-round replication-competent viruses and U87-CD4-CCR5 cells as targets. Values indicate the average and standard deviation from quadruplicate wells. Each neutralization assay was repeated at least two independent times. (A) IgGCD4, IgG1b12, F105, and M18 bind to the CD4 binding site, while 2909 recognizes a complex epitope. (B) 447D and 391-95D bind to the V3 loop, while 17b andX5 bind to CD4 induced epitopes. (C) 2F5 and 4E10 bind to the extracellular region of gp41, while 2G12 binds to a complex carbohydrate epitope; 1418 is a non-anti-HIV MAb used as a negative control. (D) Sera from macaques C640 and A141 were isolated from animals infected with SHIVSF162P4, while HIVIG is heterologous human serum IgG.
Techniques Used: Neutralization, Luciferase, Expressing, Standard Deviation, Binding Assay, Negative Control, Isolation, Infection